A structure-based framework for selective inhibitor design and optimization

被引:0
|
作者
Yurong Zou [1 ]
Tao Guo [1 ]
Zhiyuan Fu [1 ]
Zhongning Guo [1 ]
Weichen Bo [1 ]
Dengjie Yan [2 ]
Qiantao Wang [2 ]
Jun Zeng [3 ]
Dingguo Xu [4 ]
Taijin Wang [5 ]
Lijuan Chen [1 ]
机构
[1] Sichuan University,State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, West China Hospital
[2] Sichuan University,Key Laboratory of Drug
[3] University of Melbourne,Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy
[4] Sichuan University,Western Health, Faculty of Medicine Dentistry and Health Sciences
[5] Chengdu Zenitar Biomedical Technology Co.,MOE Key Laboratory of Green Chemistry and Technology, College of Chemistry
[6] Ltd.,undefined
关键词
D O I
10.1038/s42003-025-07840-3
中图分类号
学科分类号
摘要
Structure-based drug design aims to create active compounds with favorable properties by analyzing target structures. Recently, deep generative models have facilitated structure-specific molecular generation. However, many methods are limited by inadequate pharmaceutical data, resulting in suboptimal molecular properties and unstable conformations. Additionally, these approaches often overlook binding pocket interactions and struggle with selective inhibitor design. To address these challenges, we developed a framework called Coarse-grained and Multi-dimensional Data-driven molecular generation (CMD-GEN). CMD-GEN bridges ligand-protein complexes with drug-like molecules by utilizing coarse-grained pharmacophore points sampled from diffusion model, enriching training data. Through a hierarchical architecture, it decomposes three-dimensional molecule generation within the pocket into pharmacophore point sampling, chemical structure generation, and conformation alignment, mitigating instability issues. CMD-GEN outperforms other methods in benchmark tests and controls drug-likeness effectively. Furthermore, CMD-GEN excels in cases across three synthetic lethal targets, and wet-lab validation with PARP1/2 inhibitors confirms its potential in selective inhibitor design.
引用
收藏
相关论文
共 50 条
  • [1] Structure-based design of a selective heparanase inhibitor as an antimetastatic agent
    Ishida, K
    Hirai, G
    Murakami, K
    Teruya, T
    Simizu, S
    Sodeoka, M
    Osada, H
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (09) : 1069 - 1077
  • [2] Structure-based inhibitor design
    Craig, SP
    Eakin, AE
    VITAMINS AND HORMONES - ADVANCES IN RESEARCH AND APPLICATIONS, VOL 58, 2000, 58 : 149 - +
  • [3] Structure-based design of potent CDK4 selective inhibitor.
    Honma, T
    Hayashi, K
    Kawanishi, N
    Yoshizumi, T
    Hashimoto, N
    Sugimoto, T
    Nakamura, K
    Takaki, T
    Machida, T
    Fukasawa, K
    Hirai, H
    Iwama, T
    Ikeura, C
    Ikuta, M
    Kamata, K
    Suzuki-Takahashi, I
    Hayama, T
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U24 - U24
  • [4] Structure-based design of a potent and selective peptide inhibitor of caspase-3
    Yoshimori, A
    Takasawa, R
    Sakai, J
    Kobayashi, T
    Sunaga, S
    Tanuma, SI
    FEBS JOURNAL, 2005, 272 : 523 - 523
  • [5] Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
    Martin, Laetitia J.
    Koegl, Manfred
    Bader, Gerd
    Cockcroft, Xiao-Ling
    Fedorov, Oleg
    Fiegen, Dennis
    Gerstberger, Thomas
    Hofmann, Marco H.
    Hohmann, Anja F.
    Kessler, Dirk
    Knapp, Stefan
    Knesl, Petr
    Kornigg, Stefan
    Muller, Susanne
    Nar, Herbert
    Rogers, Catherine
    Rumpel, Klaus
    Schaaf, Otmar
    Steurer, Steffen
    Tallan, Cynthia
    Vakoc, Christopher R.
    Zeeb, Markus
    Zoephel, Andreas
    Pearson, Mark
    Boehmelt, Guido
    McConnell, Darryl
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (10) : 4462 - 4475
  • [6] Structure-based protein kinase inhibitor design
    Echalier, A
    Endicott, JA
    Johnson, LN
    McDonnell, J
    Noble, MEM
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 28 : S27 - S28
  • [7] Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor
    Tao, Zhi-Fu
    Wang, Xilu
    Chen, Jun
    Ingram, Justin P.
    Jin, Sha
    Judge, Russell A.
    Kovar, Peter J.
    Park, Chang
    Sun, Chaohong
    Wakefield, Brian D.
    Zhou, Li
    Zhang, Haichao
    Elmore, Steven W.
    Phillips, Darren C.
    Judd, Andrew S.
    Leverson, Joel D.
    Souers, Andrew J.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (06): : 1011 - 1016
  • [8] Structure-Based Design of a Heptavalent Anthrax Toxin Inhibitor
    Joshi, Amit
    Kate, Sandesh
    Poon, Vincent
    Mondal, Dhananjoy
    Boggara, Mohan B.
    Saraph, Arundhati
    Martin, Jacob T.
    McAlpine, Ryan
    Day, Ryan
    Garcia, Angel E.
    Mogridge, Jeremy
    Kane, Ravi S.
    BIOMACROMOLECULES, 2011, 12 (03) : 791 - 796
  • [9] Structure-based inhibitor design for reshaping bacterial morphology
    Choi, Yuri
    Park, Ji Su
    Kim, Jinshil
    Min, Kyungjin
    Mahasenan, Kiran
    Kim, Choon
    Yoon, Hye-Jin
    Lim, Sewon
    Cheon, Dae Hee
    Lee, Yan
    Ryu, Sangryeol
    Mobashery, Shahriar
    Kim, B. Moon
    Lee, Hyung Ho
    COMMUNICATIONS BIOLOGY, 2022, 5 (01)
  • [10] Structure-based design of a macrocyclic inhibitor for peptide deformylase
    Hu, XB
    Nguyen, KT
    Verlinde, CLMJ
    Hol, WGJ
    Pei, DH
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (18) : 3771 - 3774